FDA sets late 2024 de­ci­sion dead­line for Pfiz­er’s 'pan-he­mo­phil­i­a' drug: #ASH23

SAN DIEGO — The FDA is ex­pect­ed to de­cide whether to ap­prove Pfiz­er’s he­mo­phil­ia A and B an­ti­body in the fourth quar­ter of 2024, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.